Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against <i>Kit</i> ^<i>K641E</i> -mutant melanoma.

ABSTRACT: Cancer nanovaccines hold the promise for personalization, precision, and pliability by integrating all the elements essential for effective immune stimulation. An effective immune response requires communication and interplay between antigen-presenting cells (APCs), tumor cells, and immune cells to stimulate, extend, and differentiate antigen-specific and non-specific anti-tumor immune cells. The versatility of nanomedicine can be adapted to deliver both immunoadjuvant payloads and antigens from the key players in immunity (i.e., APCs and tumor cells). The imperative for novel cancer medicine is particularly pressing for less common but more devastating KIT-mutated acral and mucosal melanomas that are resistant to small molecule c-kit and immune checkpoint inhibitors. To overcome this chal

SUBMITTER: Poudel K 

PROVIDER: S-EPMC11742834 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature